Skip to main content

Caprion Will Use CellCarta to Help Vertex Pharma Discover Biomarkers

NEW YORK, March 29 (GenomeWeb News) - Vertex Pharmaceuticals will rely on data from Caprion Pharmaceuticals' CellCarta proteomics platform as part of a biomarker-discovery collaboration, the company said today.

 

As part of the deal, Caprion will identify potential pharmacodynamic biomarkers in samples from certain clinical and pre-clinical studies conducted by Vertex.

 

Caprion's platform profiles proteins and provides protein expression and identification in tissues and blood plasma.

 

Financial terms of the agreement were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.